1.20
Schlusskurs vom Vortag:
$1.16
Offen:
$1.16
24-Stunden-Volumen:
22,352
Relative Volume:
0.36
Marktkapitalisierung:
$11.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-18.98M
KGV:
-0.4205
EPS:
-2.8535
Netto-Cashflow:
$-14.55M
1W Leistung:
+15.94%
1M Leistung:
+24.99%
6M Leistung:
-30.64%
1J Leistung:
-44.95%
In 8 Bio Inc Stock (INAB) Company Profile
Firmenname
In 8 Bio Inc
Sektor
Branche
Telefon
(646) 600-6438
Adresse
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
INAB
In 8 Bio Inc
|
1.20 | 11.93M | 0 | -18.98M | -14.55M | -2.8535 |
|
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-18 | Eingeleitet | Laidlaw | Buy |
| 2022-08-30 | Eingeleitet | H.C. Wainwright | Buy |
In 8 Bio Inc Aktie (INAB) Neueste Nachrichten
Gossamer Bio Lines Up Up To $250 Million Private Placement With Milestone-Triggered Warrants - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Tech workers may be better off selling their company stock - Business Insider
TELA Bio (TELA) stake: Nantahala group reports 12.94% ownership of 5.79M shares - Stock Titan
Palisade Bio (PALI): Commodore Capital group now reports 0.0% beneficial ownership - Stock Titan
Climb Bio, Inc. (CLYM): MPM BioImpact LLC reports 0% ownership in amendment - Stock Titan
Point72 discloses 4.95% Q32 Bio Inc. (QTTB) holding in Schedule 13G/A - Stock Titan
Highbridge Capital (ANVS) discloses 6.1% Annovis Bio stake tied to 2.78M warrant shares - Stock Titan
Cabaletta Bio (CABA): T. Rowe Price reports 11.6% common stock stake - Stock Titan
Q32 Bio Inc. (QTTB) major holders cut reported stake to 0% - Stock Titan
Caballeta Bio (CABA) stake: Bain Capital Life Sciences reports 9.99% position - Stock Titan
Korro Bio (KRRO) director-affiliated funds sell 2,143 shares under 10b5-1 plan - Stock Titan
Instil Bio (Nasdaq: TIL) trims Q2 2026 loss and extends cash runway - Stock Titan
BIO-key International (BKYI) secures $2.51M and issues 1.24M new warrants in financing - Stock Titan
Palisade Bio (PALI): Soleus group reports 7.5% stake, 13.1M shares held - Stock Titan
Cabaletta Bio (CABA) lifts cash to $225M while advancing rese-cel toward BLA - Stock Titan
Valion Bio, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
Adage Capital discloses 8.43% Cabaletta Bio (CABA) stake including warrant shares - Stock Titan
Cabaletta Bio (CABA): Norges Bank reports 5.382% ownership of 8.78M shares - Stock Titan
BRVE SEC FilingsBraveheart Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Upstream Bio (NASDAQ: UPB) reports Q2 2026 loss and advances Phase 3 plans - Stock Titan
Cabaletta Bio, Inc. Stock 12‑Month Price Target Raised to $14.71, Implies 427% Upside - TradingView
Valion Bio Enters Securities Purchase Agreement With Avenue, Issues Preferred for $750,000 Milestone - tradingview.com
Climb Bio (Nasdaq: CLYM) details pipeline progress and funding into 2028 - Stock Titan
Nuvation Bio (NYSE: NUVB) posts $31.7M Q2 revenue and $62.8M loss - Stock Titan
Large equity grants for TELA Bio, Inc. (TELA) CEO Heather Getz - Stock Titan
Q32 Bio reports Q2 2026 net loss $8.9M, cash $106.3M and $200M July offering - TradingView
Q32 Bio Inc. 2Q 2026: Net loss $(8.95)M, EPS $(0.44) — 10-Q Summary - TradingView
Q32 Bio (Nasdaq: QTTB) reports AA trial gains and $200M raise - Stock Titan
Record Q2 revenue and higher net loss at ImmunityBio (NASDAQ: IBRX) - Stock Titan
Heather Getz named CEO of TELA Bio as Antony Koblish exits - TradingView
Vanguard Capital Management (CABA) discloses 8.30M-share passive stake in Cabaletta Bio - Stock Titan
Tevogen Inc. (NASDAQ: TVGN) changes name from Tevogen Bio Holdings - Stock Titan
BlackRock (PALI holder) discloses 6.0% ownership of Palisade Bio common stock - Stock Titan
Tevogen Bio Holdings Inc. Becomes Tevogen Inc. - GlobeNewswire
BlackRock (CABA) discloses 9.6M Cabaletta Bio shares under sole control - Stock Titan
Gossamer Bio Inc (GOSS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oak Hill Bio, Research Alliance III (RACC) plan SPAC merger - Stock Titan
Q32 Bio Inc. (QTTB) Stock Price, News, Quote & History - Yahoo! Finance Canada
D. E. Shaw group reports 7.1% stake in Gossamer Bio (GOSS) - Stock Titan
Cabaletta Bio (CABA) sees Millennium group report 2.07M-share, 1.3% ownership stake - Stock Titan
Kala Bio, Inc. Files Form 8-K with SEC Detailing Nasdaq Listing and Corporate Information - Minichart
Nuvation Bio sets Aug. 6 webcast on cancer treatment updates - Stock Titan
Nuvation Bio (NUVB) CFO exercises 40,000 share options and boosts holdings - Stock Titan
Valion Bio (OTC: VBIO) investor group caps ownership at 9.99% with blocker - Stock Titan
Leadership shake-up at Biorestorative Therapies (NASDAQ: BRTX) and new CEO - Stock Titan
Entera Bio (NASDAQ: ENTX) expands share authorization and equity plan pool - Stock Titan
Bio-Path Holdings (BPTH) plans AML trial restart and crypto treasury - Stock Titan
63,969 shares bought by Tang Capital in Boundless Bio, Inc. (BOLD) - Stock Titan
Q32 Bio Enters Underwriting for $18.25 Offering, Net Proceeds ~$188M; Option Lifts to ~$216M - TradingView
Q32 Bio (Nasdaq: QTTB) raises $187.6M in stock and pre-funded warrant deal - Stock Titan
Finanzdaten der In 8 Bio Inc-Aktie (INAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):